This is the week when IMNR will shine - but not right away unless the market wakes up prior to the July 4th weekend.
Dr. Valentine addresses AIDS symposium July 3rd. Immune Response IMNR has conducted a 2,500 patient test utilizing REMUNE, a patented drug to improve the body's immune system to fight AIDS based on patents assigned to the company by its co-founder, Dr. Jonas Salk. Quoting from an earlier 10-K:
"The Principal Investigator of this trial, Dr. Fred Valentine, is Professor of Medicine at New York University Medical Center and the former Chairman of the Food and Drug Administration's Antiviral Drugs Advisory Committee. The trial will be conducted at New York University Medical Center, Johns Hopkins University, Finch University of Health Sciences at Chicago Medical School, Institute of Human Virology - University of Maryland, North Shore University Hospital - New York University, University of California at Davis, University of Hawaii and Harvard University Medical School."
This is not a lightweight!
Further reference to this landmark study is in 6/21/98 New York Times magazine section (page 25 - 4th paragraph from the end).
Since the company's web page imnr.com indicates that Dr. Valentine's appearance as a presenter at this conference is a
"Late Breaker - July 3, 1998, 10:00 a.m. - Dr. Fred Valentine"
...it is safe to assume that he has something highly dramatic to present.
Betting the farm on this one is not a bad bet! Latest information discloses that 35 institutional investors own 21.28% and insiders 12.44% of 22,869,000 shares outstanding. Assuming that institutional investors will hold on for a while, not too many shares for the public at large - it will, in my opinion, be highly volatile this coming week and a great celebratory wrap-up to the 4th of July weekend!
|
